Sugi Predict

Sugi Predict / Compounds / SCHEMBL499504

SCHEMBL499504

SCHEMBL499504

CSc1ccc(C(=O)/C=C/c2cc(C)c(O)c(C)c2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.67
▸ ALDH1A1 P00352 1/20 0.67
▸ LMNA P02545 1/20 0.67
▸ GAA P10253 1/20 0.67
▸ MAPT P10636 1/20 0.67
▸ CASP3 P42574 1/20 0.67
▸ RAB9A P51151 1/20 0.67
▸ KMT2A Q03164 1/20 0.67
▸ SENP8 Q96LD8 1/20 0.67
▸ SENP7 Q9BQF6 1/20 0.67
▸ SENP6 Q9GZR1 1/20 0.67
▸ PPARG P37231 1/20 0.64
▸ PPARD Q03181 1/20 0.64
▸ PPARA Q07869 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL499505 1.00 MEN1 (0.67) MEN1ALDH1A1LMNAGAAMAPT
SCHEMBL9339706 0.87 MAPT (0.68) MEN1ALDH1A1LMNAGAAMAPT
SCHEMBL9339697 0.87 MAPT (0.68) MEN1ALDH1A1LMNAGAAMAPT
SCHEMBL28600841 0.86 MAPT (0.68) MEN1ALDH1A1LMNAGAAMAPT
SCHEMBL28608357 0.85 PPARG (0.70) MEN1ALDH1A1LMNAGAAMAPT
SCHEMBL21897755 0.85 — —
SCHEMBL13359041 0.84 MAPT (0.66) MEN1MAPTRAB9AKMT2A
SCHEMBL4462257 0.84 MAPT (0.65) MEN1ALDH1A1LMNAGAAMAPT
SCHEMBL4462260 0.84 MAPT (0.65) MEN1ALDH1A1LMNAGAAMAPT
SCHEMBL3969013 0.83 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113121394-B Preparation method of phenoxyacetic acid derivative 中国药科大学 2022-11-08 — — CN claimed
CN-113121394-A Preparation method of phenoxyacetic acid derivative 中国药科大学 2021-07-16 — — CN claimed
CN-113230240-B 1,3-diphenylprop-2-en-1-one derivative and application thereof 广州医科大学 2022-12-27 — — CN disclosed
CN-113121394-B Preparation method of phenoxyacetic acid derivative 中国药科大学 2022-11-08 — — CN disclosed
CN-113121394-B Preparation method of phenoxyacetic acid derivative 中国药科大学 2022-11-08 — — CN disclosed
CN-109316601-B Pharmaceutical composition and use thereof 武汉朗来科技发展有限公司 2021-11-09 — — CN disclosed
CN-113230240-A 1, 3-diphenylprop-2-en-1-one derivative and application thereof 广州医科大学 2021-08-10 — — CN disclosed
CN-113121394-A Preparation method of phenoxyacetic acid derivative 中国药科大学 2021-07-16 — — CN disclosed
CN-113121394-A Preparation method of phenoxyacetic acid derivative 中国药科大学 2021-07-16 — — CN disclosed
US-20210101866-A1 PROCESS FOR THE PREPARATION OF ELAFIBRANOR AND NOVEL SYNTHESIS INTERMEDIATES ADVITECH ADVISORY AND TECHNOLOGIES SA (CH) 2021-04-08 — — US disclosed
EP-3518912-B1 DUAL-ACTION ELAFIBRANOR METFORMIN SALT FOR TREATING OBESITY ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND HYPERTRIGLYCERIDAEMIA NASHPHARM (FR) 2020-12-30 — — EP disclosed
US-20060142611-A1 Preparation of 1,3-diphenylprop-2-en-1-one derivatives GENFIT (FR) 2006-06-29 — — US disclosed
EP-1644312-A1 PREPARATION OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES Genfit (FR) 2006-04-12 — — EP disclosed
US-20050176808-A1 Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof GENFIT (FR) 2005-08-11 — — US disclosed
US-20050171149-A1 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof GENFIT (FR) 2005-08-04 — — US disclosed
EP-1525177-A1 SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF Genfit (FR) 2005-04-27 — — EP disclosed
EP-1519908-A2 COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF Genfit (FR) 2005-04-06 — — EP disclosed
WO-2005005369-A1 PREPARATION OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES GENFIT (FR) 2005-01-20 — — WO disclosed
WO-2004005243-A2 COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES GENFIT (FR) 2004-01-15 — — WO disclosed
WO-2004005233-A1 SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF GENFIT (FR) 2004-01-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210101866-A1 PROCESS FOR THE PREPARATION OF ELAFIBRANOR AND NOVEL SYNTHESIS INTERMEDIATES FDPS, CYP4F11, CYP4F3 MEN1 2216/4885ALDH1A1 435/4885LMNA 3196/4885
US-20050176808-A1 Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof PGF, PTGS1, PTGES3 MEN1 3869/4885ALDH1A1 231/4885LMNA 1823/4885
US-20050171149-A1 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof BRCA1, LOXL1, APOL1 MEN1 1522/4885ALDH1A1 518/4885LMNA 100/4885
US-20060142611-A1 Preparation of 1,3-diphenylprop-2-en-1-one derivatives DPEP1, PKD1, ENPP1 MEN1 1780/4885ALDH1A1 238/4885LMNA 894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.